Skip to main content
. 2017 Apr 1;26(4):693–702. doi: 10.3727/096368916X694184

Figure 2.

Figure 2.

Regulator of cell cycle (rgcc) protein levels are increased in mild cognitive impairment (MCI) and Alzheimer's disease (AD). (A) Representative Western blot shows greater RCGG immunoreactivity (~15 kDa) in tissue extracts derived from MCI and AD cases compared to no cognitive impairment (NCI) cases; levels of β-actin were equivalent across samples. (B) Box plots show relative quantitative measurements of RGCC immunoreactivity normalized to β-actin signals (mean+max/min; arbitrary units) in the three diagnostic groups. *p < 0.05 versus NCI, via one-way analysis of variance (ANOVA) with Bonferroni post hoc comparisons.